Impact Factor
4.15
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.76
3,620 total citations
h5-index
61
h5 depth signal
Cited share
80.6%
644 of 799
Total citations
3,620
Citation footprint
Metric signal
4.99
External metric anchor
Self-citation
1.8%
65 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,482
China
572
Italy
377
United Kingdom
272
France
269
Citing Fields of Research
Oncology
2,001
Immunology
634
Breast Cancer
632
Lung Cancer
515
Liver & Colon Cancer
466
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,563
Articles tracked across the journal lifetime
Indexed publication set
799
644 cited publications
Last 12 months
753
62.8 publications/month
Open access share
98.0%
738 OA publications in the last year
Leading citing country
United States
2,482 citing publications
Leading citing field
Oncology
2,001 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v4n1, 1999-
v4n1, 1999-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Immunology
Urology
Liver & Colon Cancer
Lung Cancer
Broad Categories
Neoplasms
Urology
Lung Cancer
Immunology
Liver & Colon Cancer
Palliative Care
Breast Cancer
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/oncolo/oyag315
Open DOI
Clinical Endpoints in Trials of Metastasis-Directed Therapy in Oligometastatic Cancer: A Systematic Review and Surrogacy Analysis
Background: The oligometastatic state is characterized by limited metastatic burden for which metastasis-directed therapy (MDT) may provide durable control. Endpoint selection in MDT trials is poorly standardized and may not reflect long...
02
DOI 10.1093/oncolo/oyag411
Open DOI
Integrating ctDNA-Based ESR1 m Monitoring Into First-Line Care for ER+, HER2– Advanced Breast Cancer: A Consensus Workflow
Circulating tumor DNA (ctDNA) is an emerging tool in precision oncology that enables noninvasive tumor profiling, detection of minimal residual disease, and treatment monitoring. Furthermore, routine ctDNA analyses offer the potential to...
03
DOI 10.1093/oncolo/oyag404
Open DOI
Whole Genome Sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors
Background: Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera™ ...
04
DOI 10.1093/oncolo/oyag402
Open DOI
Aspirational Autonomy and Psychedelic-Assisted Therapy in Advanced Cancer: Ethical Lessons from Clinical Cases
Psychedelic-assisted therapy (PAT) is increasingly discussed as a potential intervention for anxiety, depression, and existential distress among patients with advanced cancer. Yet the ethical challenges of PAT for patients approaching th...
05
DOI 10.1093/oncolo/oyag417
Open DOI
Cerebrospinal Fluid Tumor-Derived DNA Analysis Aids in the Diagnosis of Postpartum Diffuse Midline Glioma
Background: Gliomas diagnosed during pregnancy or postpartum pose diagnostic and management challenges. Neurologic symptoms may be attributed to physiological changes of pregnancy or the postpartum state, possibly delaying evaluation. Wh...
06
DOI 10.1093/oncolo/oyag414
Open DOI
A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine resistant metastatic breast cancer
Background: Patients with endocrine-resistant hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) have limited effective treatment options. Heat shock protein 90 (HSP90) regulates estrogen receptor stability and...
07
DOI 10.1093/oncolo/oyag416
Open DOI
Association of Irreversible Electroporation Treatment with Overall Survival in Stage III Pancreatic Ductal Adenocarcinoma: DIRECT Registry Results
Background: Irreversible electroporation (IRE) is used in selected patients with Stage III pancreatic ductal adenocarcinoma (PDAC), but its association with survival relative to standard-of-care (SOC) therapy remains uncertain. Methods: ...
08
09
DOI 10.1093/oncolo/oyag410
Open DOI
Resilience in Symptom Response as an Adaptive Capacity: Methodological and Theoretical Clarifications
10
DOI 10.1093/oncolo/oyag409
Open DOI
Durable Response to Vebreltinib in Heavily Pretreated MET -Amplified Intrahepatic Cholangiocarcinoma: A Case Report
Background: MET amplification, although detected in only 2% to 5% of intrahepatic cholangiocarcinomas (ICC), represents an actionable oncogenic driver. Treatment options after failure of first-line immunochemotherapy remain limited, and ...
Bibliographical & Catalog Notes
Print issues ceased with v. 25 (2020).
Also issued online.
v. 3, no. 2 (April 15, 1998)19991214 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper